FLXN Flexion Therapeutics Inc.

11.45
+0.66  (+6%)
Previous Close 10.79
Open 10.94
Price To Book 6
Market Cap 435,015,625
Shares 37,992,631
Volume 580,190
Short Ratio
Av. Daily Volume 573,500

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 enrolment paused due to non-safety issue - May 8, 2019.
Zilretta
Osteoarthritis of the hip
Approval announced October 6, 2017.
Zilretta - FX006
Osteoarthritis of the knee
Phase 2 top-line data released November 2016.
Zilretta - FX006
Osteoarthritis of the knee with type 2 adult diabetes
PDUFA date for sNDA filing October 14, 2019.
Zilretta - FX006 repeat
Osteoarthritis of the knee
Top-line safety data due 2Q 2018.
Zilretta - FX006
Osteoarthritis of the knee
Clinical trials to commence 2H 2019 following IND filing.
FX201
Osteoarthritis (OA)

Latest News

  1. Flexion Therapeutics Presents New Data Evaluating Repeat Administration of ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) in Patients with Advanced Knee OA
  2. Flexion Therapeutics, Inc. (NASDAQ:FLXN): When Will It Breakeven?
  3. Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  4. Here’s What Hedge Funds Think About Flexion Therapeutics Inc (FLXN)
  5. Flexion Therapeutics Named one of Boston Business Journal’s Best Places to Work for the Third Consecutive Year
  6. Flexion Therapeutics to Present at the BMO Capital Markets 2019 Prescriptions for Success Healthcare Conference
  7. Edited Transcript of FLXN earnings conference call or presentation 8-May-19 8:30pm GMT
  8. Flexion Therapeutics Announces Issuance of New U.S. Patent Covering FX201 a Gene Therapy Product Candidate for the Treatment of Osteoarthritis
  9. If You Had Bought Flexion Therapeutics (NASDAQ:FLXN) Stock A Year Ago, You'd Be Sitting On A 56% Loss, Today
  10. These 3 Small-Cap Healthcare Stocks Reported Big Updates This Month
  11. Flexion Therapeutics to Present at the 2019 RBC Capital Markets Global Healthcare Conference
  12. Flexion Therapeutics, Inc. (FLXN) Q1 2019 Earnings Call Transcript
  13. Flexion Therapeutics Announces Publication of Pooled Analysis of Phase 2/3 Data on Use of Rescue Medication with ZILRETTA® (triamcinolone acetonide extended-release injectable suspension)
  14. Here's Why Flexion Therapeutics Jumped as Much as 18.4% Today
  15. Chevron, Conduent, Flexion, and More: Stocks in the Spotlight
  16. Flexion Therapeutics (FLXN) Reports Q1 Loss, Lags Revenue Estimates
  17. Flexion Therapeutics: 1Q Earnings Snapshot
  18. Flexion Therapeutics Reports First-Quarter 2019 Financial Results and Recent Business Highlights